Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK.

J Clin Oncol. 2018 Dec 13:JCO2018782276. doi: 10.1200/JCO.2018.78.2276. [Epub ahead of print]

PMID:
30557521
2.

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E.

Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29.

3.

Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of veterans health affairs data.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Di Stefano J, Knepley C, Limaye S, Mamtani R, Wisnivesky J, Damjanov N, Langer CJ, Cohen RB, Sigel K.

Cancer. 2018 Oct 20. doi: 10.1002/cncr.31816. [Epub ahead of print]

PMID:
30341983
4.

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.

Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL.

JAMA Oncol. 2018 Oct 11. doi: 10.1001/jamaoncol.2018.4305. [Epub ahead of print]

PMID:
30325992
5.

Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.

Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, Bauml JM, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, Vang R, Dallas M, Oyola S, Duff S, Esser M, Kumar R, Weiner D, Csiki I, Bagarazzi ML.

Clin Cancer Res. 2019 Jan 1;25(1):110-124. doi: 10.1158/1078-0432.CCR-18-1763. Epub 2018 Sep 21.

PMID:
30242022
6.

Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K.

J Natl Cancer Inst. 2018 Sep 18. doi: 10.1093/jnci/djy133. [Epub ahead of print]

PMID:
30239887
7.

Barriers to physical activity: a study of academic and community cancer survivors with pain.

Romero SAD, Brown JC, Bauml JM, Hay JL, Li QS, Cohen RB, Mao JJ.

J Cancer Surviv. 2018 Dec;12(6):744-752. doi: 10.1007/s11764-018-0711-y. Epub 2018 Sep 4.

PMID:
30182150
8.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2018 May 21. doi: 10.1007/s10637-018-0610-0. [Epub ahead of print]

PMID:
29781056
9.

Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.

Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M.

Cancer Chemother Pharmacol. 2018 Jul;82(1):77-86. doi: 10.1007/s00280-018-3560-5. Epub 2018 May 2.

PMID:
29721850
10.

The association between fatigue and pain symptoms and decreased physical activity after cancer.

Romero SAD, Jones L, Bauml JM, Li QS, Cohen RB, Mao JJ.

Support Care Cancer. 2018 Oct;26(10):3423-3430. doi: 10.1007/s00520-018-4203-4. Epub 2018 Apr 19.

PMID:
29675547
11.

Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.

Aggarwal C, Haas AR, Metzger S, Aguilar LK, Aguilar-Cordova E, Manzanera AG, Gómez-Hernández G, Katz SI, Alley EW, Evans TL, Bauml JM, Cohen RB, Langer CJ, Albelda SM, Sterman DH.

Mol Ther. 2018 May 2;26(5):1198-1205. doi: 10.1016/j.ymthe.2018.02.015. Epub 2018 Feb 21.

PMID:
29550074
12.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B.

Am J Clin Oncol. 2018 Feb 21. doi: 10.1097/COC.0000000000000429. [Epub ahead of print]

13.

Effect of Prophylactic Cranial Irradiation on Overall Survival in Metastatic Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.

Sharma S, McMillan MT, Doucette A, Cohen RB, Berman A, Levin W, Simone CB 2nd, Shabason J.

Clin Lung Cancer. 2018 May;19(3):260-269.e3. doi: 10.1016/j.cllc.2017.12.003. Epub 2017 Dec 14.

PMID:
29358031
14.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Stein MN, Abdul Razak AR, Dotti K, Santoro A, Cohen RB, Gould M, Saraf S, Stein K, Han SW.

PLoS One. 2017 Dec 28;12(12):e0189848. doi: 10.1371/journal.pone.0189848. eCollection 2017.

15.

Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.

Aggarwal C, Wang X, Ranganathan A, Torigian D, Troxel A, Evans T, Cohen RB, Vaidya B, Rao C, Connelly M, Vachani A, Langer C, Albelda S.

Lung Cancer. 2017 Oct;112:118-125. doi: 10.1016/j.lungcan.2017.08.008. Epub 2017 Aug 12.

PMID:
29191584
16.

The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer.

Kesarwala AH, Lu DJ, Xanthopoulos E, Apisarnthanarax S, Cengel KA, Evans TL, Aggarwal C, Cohen RB, Langer CJ, Rengan R, Simone CB 2nd.

Clin Lung Cancer. 2018 Mar;19(2):e205-e209. doi: 10.1016/j.cllc.2017.10.001. Epub 2017 Oct 12.

PMID:
29153967
17.

Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.

Aggarwal C, Cohen RB, Yu E, Hwang WT, Bauml JM, Alley E, Evans TL, Langer CJ.

Clin Lung Cancer. 2018 Mar;19(2):157-162. doi: 10.1016/j.cllc.2017.10.007. Epub 2017 Oct 19.

PMID:
29129435
18.

Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.

Marmarelis M, Thompson JC, Aggarwal C, Evans TL, Carpenter E, Cohen RB, Langer CJ, Bauml J.

Ann Transl Med. 2017 Sep;5(18):380. doi: 10.21037/atm.2017.07.29. Review.

19.

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, Thanigaimani P, Cheng JD, Hansen AR.

J Clin Oncol. 2017 Dec 20;35(36):4050-4056. doi: 10.1200/JCO.2017.73.3675. Epub 2017 Aug 24.

PMID:
28837405
20.

Delayed osteomyelitis resulting from an extension injury of the cervical spine: case report.

Palmer V, Cohen RB, Braffman B, Brockmeyer DL, Spader HS.

J Neurosurg Pediatr. 2017 Oct;20(4):388-392. doi: 10.3171/2017.5.PEDS1777. Epub 2017 Aug 11.

PMID:
28799857
21.

The Influence of Lordotic cages on creating Sagittal Balance in the CMIS treatment of Adult Spinal Deformity.

Anand N, Cohen RB, Cohen J, Kahndehroo B, Kahwaty S, Baron E.

Int J Spine Surg. 2017 Jun 30;11:23. doi: 10.14444/4023. eCollection 2017.

22.

Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.

Rwigema JM, Verma V, Lin L, Berman AT, Levin WP, Evans TL, Aggarwal C, Rengan R, Langer C, Cohen RB, Simone CB 2nd.

Cancer. 2017 Nov 1;123(21):4244-4251. doi: 10.1002/cncr.30870. Epub 2017 Jul 5.

23.

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

Infante JR, Cohen RB, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, LoRusso PM.

Invest New Drugs. 2017 Oct;35(5):669. doi: 10.1007/s10637-017-0479-3. No abstract available.

PMID:
28676972
24.

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors.

Patel SH, Rimner A, Cohen RB.

Transl Lung Cancer Res. 2017 Apr;6(2):186-195. doi: 10.21037/tlcr.2017.03.04. Review.

25.

Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer.

Trifiletti DM, Smith A, Mitra N, Grover S, Lukens JN, Cohen RB, Read P, Mendenhall WM, Lin A, Swisher-McClure S.

J Clin Oncol. 2017 May 10;35(14):1550-1560. doi: 10.1200/JCO.2016.68.2336. Epub 2017 Feb 13.

PMID:
28475848
26.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.

Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J.

Ann Oncol. 2017 May 1;28(5):1036-1041. doi: 10.1093/annonc/mdx029.

27.

Comparison of a Newer Versus Older Protocol for Circumferential Minimally Invasive Surgical (CMIS) Correction of Adult Spinal Deformity (ASD)-Evolution Over a 10-Year Experience.

Anand N, Cohen JE, Cohen RB, Khandehroo B, Kahwaty S, Baron E.

Spine Deform. 2017 May;5(3):213-223. doi: 10.1016/j.jspd.2016.12.005.

PMID:
28449965
28.

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

Infante JR, Cohen RB, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, LoRusso PM.

Invest New Drugs. 2017 Oct;35(5):576-588. doi: 10.1007/s10637-017-0459-7. Epub 2017 Apr 19. Erratum in: Invest New Drugs. 2017 Jul 5;:.

29.

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ.

Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25.

PMID:
28285682
30.

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.

LoRusso PM, Infante JR, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, Cohen RB.

BMC Cancer. 2017 Mar 6;17(1):173. doi: 10.1186/s12885-017-3143-6.

31.

Unsupervised exercise in survivors of human papillomavirus related head and neck cancer: how many can go it alone?

Bauml J, Kim J, Zhang X, Aggarwal C, Cohen RB, Schmitz K.

J Cancer Surviv. 2017 Aug;11(4):462-468. doi: 10.1007/s11764-017-0604-5. Epub 2017 Feb 13.

PMID:
28194641
32.

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM, Leohr J, Lin AB, Li LQ, McGlothlin A, Farrington DL, Westin EH, Cohen RB.

Cancer Chemother Pharmacol. 2017 Feb;79(2):315-326. doi: 10.1007/s00280-016-3205-5. Epub 2017 Jan 17.

PMID:
28097385
33.

Transoral Robotic Surgery-Assisted Endoscopy With Primary Site Detection and Treatment in Occult Mucosal Primaries.

Hatten KM, O'Malley BW Jr, Bur AM, Patel MR, Rassekh CH, Newman JG, Cannady SB, Chalian AA, Hodnett BL, Lin A, Lukens JN, Cohen RB, Bauml JM, Montone KT, Livolsi VA, Weinstein GS.

JAMA Otolaryngol Head Neck Surg. 2017 Mar 1;143(3):267-273. doi: 10.1001/jamaoto.2016.3419.

PMID:
27930761
34.

Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer.

Bagley SJ, Vitale S, Zhang S, Aggarwal C, Evans TL, Alley EW, Cohen RB, Langer CJ, Blair IA, Vachani A, Whitehead AS.

Clin Lung Cancer. 2017 Mar;18(2):e143-e149. doi: 10.1016/j.cllc.2016.10.010. Epub 2016 Oct 26.

35.

Risk of lymph node metastasis and recommendations for elective nodal treatment in squamous cell carcinoma of the nasal cavity and maxillary sinus: a SEER analysis.

Ahn PH, Mitra N, Alonso-Basanta M, Palmer JN, Adappa ND, O'Malley BW Jr, Rassekh C, Chalian A, Cohen RB, Lin A.

Acta Oncol. 2016 Sep - Oct;55(9-10):1107-1114. doi: 10.1080/0284186X.2016.1216656. Epub 2016 Aug 11.

PMID:
27685421
36.

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J.

Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20.

37.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.

Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6.

38.

Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".

Bauml JM, Troxel A, Epperson CN, Cohen RB, Schmitz K, Stricker C, Shulman LN, Bradbury A, Mao JJ, Langer CJ.

Lung Cancer. 2016 Oct;100:110-113. doi: 10.1016/j.lungcan.2016.08.002. Epub 2016 Aug 16.

39.

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, Nixon A, Turnbull B, Garmey EG, Gunnarsson O, Waliki M, Ciconte J, Jayaraman L, Senderowicz A, Tellez AB, Hennessy M, Piscitelli A, Vaughn D, Smith A, Haas NB.

Ann Oncol. 2016 Aug;27(8):1579-85. doi: 10.1093/annonc/mdw188. Epub 2016 Jun 8.

40.

Immunotherapy for head and neck cancer: latest developments and clinical potential.

Bauml JM, Cohen RB, Aggarwal C.

Ther Adv Med Oncol. 2016 May;8(3):168-75. doi: 10.1177/1758834016631529. Epub 2016 Feb 16. Review.

41.

Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.

Weiss JM, Bagley S, Hwang WT, Bauml J, Olson JG, Cohen RB, Hayes DN, Langer C.

Cancer. 2016 Aug 1;122(15):2350-5. doi: 10.1002/cncr.30067. Epub 2016 May 19.

42.

Acupuncture for Dyspnea in Lung Cancer: Results of a Feasibility Trial.

Bauml J, Haas A, Simone CB 2nd, Li SQ, Cohen RB, Langer CJ, Mao JJ.

Integr Cancer Ther. 2016 Sep;15(3):326-32. doi: 10.1177/1534735415624138. Epub 2016 Apr 24.

43.

Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential Treatment.

Maquilan G, Grover S, Xanthopoulos E, Evans TL, Aggarwal C, Langer CJ, Cohen RB, Stevenson JP, Simone CB 2nd, Rengan R.

Am J Clin Oncol. 2018 Apr;41(4):391-395. doi: 10.1097/COC.0000000000000288.

PMID:
27100960
44.

Cancer Communication in the Social Media Age.

Sedrak MS, Cohen RB, Merchant RM, Schapira MM.

JAMA Oncol. 2016 Jun 1;2(6):822-3. doi: 10.1001/jamaoncol.2015.5475. No abstract available.

PMID:
26940041
45.

A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.

Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H.

Clin Cancer Res. 2016 May 1;22(9):2146-54. doi: 10.1158/1078-0432.CCR-15-1622. Epub 2015 Dec 11.

46.

Nodal metastasis and elective nodal level treatment in sinonasal small-cell and sinonasal undifferentiated carcinoma: a surveillance, epidemiology and end results analysis.

Ahn PH, Mitra N, Alonso-Basanta M, Adappa ND, Palmer JN, O'Malley BW Jr, Rassekh CH, Chalian A, Cohen RB, Lin A.

Br J Radiol. 2016;89(1058):20150488. doi: 10.1259/bjr.20150488. Epub 2015 Nov 11.

47.

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.

Brady AK, McNeill JD, Judy B, Bauml J, Evans TL, Cohen RB, Langer C, Vachani A, Aggarwal C.

Oncotarget. 2015 Oct 6;6(30):30287-94. doi: 10.18632/oncotarget.4711.

48.

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.

Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD.

Clin Cancer Res. 2016 Feb 15;22(4):847-57. doi: 10.1158/1078-0432.CCR-15-1338. Epub 2015 Sep 30.

49.

Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.

Faivre SJ, Olszanski AJ, Weigang-Köhler K, Riess H, Cohen RB, Wang X, Myrand SP, Wickremsinhe ER, Horn CL, Ouyang H, Callies S, Benhadji KA, Raymond E.

Invest New Drugs. 2015 Dec;33(6):1206-16. doi: 10.1007/s10637-015-0286-7. Epub 2015 Sep 16.

PMID:
26377590
50.

Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents.

Dranitsaris G, Cohen RB, Acton G, Keltner L, Price M, Amir E, Podack ER, Schreiber TH.

J Immunother. 2015 Sep;38(7):259-66. doi: 10.1097/CJI.0000000000000089.

PMID:
26261889

Supplemental Content

Loading ...
Support Center